CLINICAL TRIALS PROFILE FOR EVOLOCUMAB
✉ Email this page to a colleague
All Clinical Trials for evolocumab
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01375764 ↗ | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects | Completed | Amgen | Phase 2 | 2011-07-28 | The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin. |
NCT01375777 ↗ | Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels | Completed | Amgen | Phase 2 | 2011-07-06 | The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia. |
NCT01516879 ↗ | Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study | Completed | Amgen | Phase 3 | 2012-01-05 | To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy. |
NCT01588496 ↗ | Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities | Completed | Amgen | Phase 2/Phase 3 | 2012-04-05 | A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH). |
NCT01763827 ↗ | Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 | Completed | Amgen | Phase 3 | 2013-01-21 | The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less. |
NCT01763866 ↗ | LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 | Completed | Amgen | Phase 3 | 2013-01-15 | The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia. |
NCT01763905 ↗ | Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 | Completed | Amgen | Phase 3 | 2013-01-24 | The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for evolocumab
Condition Name
Clinical Trial Locations for evolocumab
Trials by Country
Clinical Trial Progress for evolocumab
Clinical Trial Phase
Clinical Trial Sponsors for evolocumab
Sponsor Name